Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 58

Sort by

Sort Order Select

Journal Articles

Transcriptomic landscape of circulating mononuclear phagocytes in Langerhans cell histiocytosis at the single-cell level

Blood (2021) 138 (14): 1237–1248.

https://doi.org/10.1182/blood.2020009064

Published: 2021

Includes: Supplemental data

Journal Articles

Classification and Prognosis of Central Nervous System Involvement in Erdheim-Chester Disease

Fleur Cohen-Aubart, MD PhD, Ahmed Idbaih, MD PhD, Damien Galanaud, MD PhD, Bruno Law-Ye, MD, Jean-François Emile, MD PhD, Frédéric Charlotte, MD, Jean Donadieu, MD PhD, Zahir Amoura, MD MSc, Julien Haroche

Blood (2019) 134 (Supplement_1): 4272.

https://doi.org/10.1182/blood-2019-130606

Published: 2019

Journal Articles

Low-Dose BRAF-Inhibitors in the Treatment of Histiocytic Disorders with the BRAF-V600E Mutation

Gordon Ruan, MD, Gaurav Goyal, MBBS, Jithma P. Abeykoon, MD, N. Nora Bennani, MD, Karen Rech, MD, Jason Young, MD, Mithun Vinod Shah, MD PhD, Ronald S. Go, MD

Blood (2019) 134 (Supplement_1): 5895.

https://doi.org/10.1182/blood-2019-124891

Published: 2019

Journal Articles

First Line Chemo-Free Therapy with the BRAF Inhibitor Vemurafenib Combined with Obinutuzumab Is Effective in Patients with Hcl

Jae H. Park, MD, Madhulika Shukla, Jose M Salcedo, Shreya Vemuri, Julie C Kinoshita, Marissa D Smith, Eric S. Winer, MD, Omar Abdel-Wahab, MD, Martin S. Tallman, MD

Blood (2019) 134 (Supplement_1): 3998.

https://doi.org/10.1182/blood-2019-124478

Published: 2019

Journal Articles

Moxetumomab Pasudotox-Tdfk in Heavily Pretreated Patients with Relapsed/Refractory Hairy Cell Leukemia (HCL): Long-Term Follow-up from the Pivotal Phase 3 Trial

Robert J. Kreitman, MD, Claire E. Dearden, MD FRCP, FRCPath, Pier Luigi Luigi Zinzani, MD, Julio Delgado, Tadeusz Robak, MD, Philipp D le Coutre, MD, Bjorn T. Gjertsen, MD PhD, Xavier Troussard, MD, Gail J. Roboz, MD, Lionel Karlin, MD, Douglas E Gladstone, MD, Nataliya Kuptsova-Clarkson, MD, Shiyao Liu, Priti Patel, MD, Wyndham Wilson, MD, Ira Pastan, MD, Francis J. Giles, MD FRCPI, FRCPath

Blood (2019) 134 (Supplement_1): 2808.

https://doi.org/10.1182/blood-2019-122307

Published: 2019

Journal Articles

Identification of Genotype-Specific Therapeutic Vulnerabilities By Comparative Dynamic BH3 Profiling Analysis of Human and Murine CLL

Shanye Yin, PhD, Salma Parvin, PhD, Elisa Ten Hacken, PhD, Rebecca Valentin, MD, Heather Joyal, Laura Z. Rassenti, PhD, Emanuela M. Ghia, PhD, Thomas J. Kipps, MD PhD, Donna S Neuberg, ScD, Lili Wang, MD PhD, Matthew S. Davids, MD, Ruben D. Carrasco, MD PhD, Anthony G. Letai, MD PhD, Catherine J. Wu, MD

Blood (2019) 134 (Supplement_1): 4281.

https://doi.org/10.1182/blood-2019-127293

Published: 2019

Journal Articles

High-Risk Langerhans Cell Histiocytosis in Infants Exhibits Malignant Features in a Xenograft Model but Responds Durably to Targeted Therapy

Lynn Lee, MD, Mary Christa Krupski, DO, MPH, Jason Clark, MS, Robert B. Lorsbach, MD PhD, Michael Grimley, MD, Matthew Burwinkel, Adam S. Nelson, MBBS, Ashish R Kumar, MD PhD

Blood (2018) 132 (Supplement 1): 4323.

https://doi.org/10.1182/blood-2018-99-119383

Published: 2018

Journal Articles

Acquired Resistance to BRAF Inhibition in Hcl Is Rare and Retreatment with Vemurafenib at Relapse Can Induce High Response Rates: Final Results of a Phase II Trial of Vemurafenib in Relapsed Hcl

Jae H. Park, MD, Jeong-Ok Lee, MD, Richard M. Stone, MD, Alan Saven, MD, Jessica K. Altman, MD, Michael R. Grever, MD, Kanti R Rai, MD, Shreya Vemuri, Omar I Abdel-Wahab, MD, Martin S. Tallman, MD

Blood (2018) 132 (Supplement 1): 392.

https://doi.org/10.1182/blood-2018-99-119949

Published: 2018

Journal Articles

Clinical and PET Responses to Long-Term High-Dose Interferon-α Treatment Among Patients with Erdheim-Chester Disease

Xinxin Cao, Na Niu, Jian Sun, Hao Cai, Feng-dan Wang, Yi-ning Wang, Ding-rong Zhong, Ming-hui Duan, MD, Dao-bin Zhou, MD, Jian Li, MD

Blood (2018) 132 (Supplement 1): 5215.

https://doi.org/10.1182/blood-2018-99-114040

Published: 2018

Journal Articles

Treatment with Combination of Dabrafenib and Trametinib in Patients with Recurrent/Refractory BRAF V600E-Mutated Hairy Cell Leukemia (HCL)

Robert J. Kreitman, MD, Philippe Moreau, Martin Hutchings, MD, Anas Gazzah, MD, Jean-Yves Blay, MD PhD, Zev A. Wainberg, MD, Alexander Stein, MD, Sascha Dietrich, MD, Maja J.A. de Jonge, MD, Wolfgang Willenbacher, MD, Jacques De Greve, MD, Evgeny Arons, PhD, Farhad Ravandi, MD, Fatima Rangwala, Paul Burgess, Bijoyesh Mookerjee, Vivek Subbiah, MD

Blood (2018) 132 (Supplement 1): 391.

https://doi.org/10.1182/blood-2018-99-113135

Published: 2018

Journal Articles

Long-Term Follow-up Identifies Double Hit and Key Mutations As Impacting Progression Free and Overall Survival in Multiple Myeloma

Cody Ashby, PhD, Eileen Boyle, Ruslana G. Tytarenko, MS, Hongwei Wang, MS, Adam Rosenthal, MS, Purvi Patel, Yan Wang, Shayu Deshpande, Maria Ortiz, Erin Flynt, Antje Hoering, PhD, Sharmilan Thanendrarajan, MD, Carolina D. Schinke, MD, Maurizio Zangari, MD, Frits van Rhee, MD PhD, Bart Barlogie, MD PhD, Anjan Thakurta, PhD, Gareth Morgan, MD, Brian A Walker, PhD

Blood (2018) 132 (Supplement 1): 110.

https://doi.org/10.1182/blood-2018-99-113045

Published: 2018

Journal Articles

Feasibility and Benefit of Molecularly-Informed Enrollment into Personalized Therapies or Early Phase Trials for Patients with Relapsed or Refractory Multiple Myeloma

Tarek Assi, Jean-Marie Michot, MD, Toni Ibrahim, MD MSc, Fabien Le Bras, Karim Belhadj, Julien Lazarovici, MD, David Ghez, MD PhD, Julien Rossignol, MD PhD, Veronique Vergé, Julia Arfi-Rouche, Sophie Cotteret, Christophe Massard, Jean-Charles Soria, Alina Danu, MD, Vincent Ribrag, MD

Blood (2018) 132 (Supplement 1): 2001.

https://doi.org/10.1182/blood-2018-99-111050

Published: 2018

Journal Articles

Clonal Hematopoiesis in Erdheim-Chester Disease

Julien Haroche, MD PhD, Stéphanie Poulain, MD PhD, Alice Marceau-Renaut, PharmD, Aline Renneville, Catherine Settegrana, Karim Maloum, Damien Roos-Weil, Florence Nguyen-Khac, MD PhD, Jean Donadieu, MD, Jean-François Emile, MD PhD, Zahir Amoura, Fleur Cohen-Aubart, MD PhD

Blood (2017) 130 (Supplement 1): 3788.

https://doi.org/10.1182/blood.V130.Suppl_1.3788.3788

Published: 2017

Journal Articles

Phase 2 Trial of Single-Agent Cobimetinib for Adults with BRAF V600-Mutant and Wild-Type Histiocytic Disorders

Eli L Diamond, MD, Benjamin H Durham, MD BS, Ahmet Dogan, MD PhD, David M. Hyman, MD, Raajit K. Rampal, MD PhD, Gary Ulaner, MD, Lynn Brody, MD, Omar Abdel-Wahab, MD

Blood (2017) 130 (Supplement 1): 257.

https://doi.org/10.1182/blood.V130.Suppl_1.257.257

Published: 2017

Journal Articles

BRAF-V600E in Peripheral Mononuclear Cells and Microglia-like Brain Cells Suggest Hematopoietic Origin of Langerhans Cell Histiocytosis-Associated Neurodegeneration

Blood (2017) 130 (Supplement 1): 2930.

https://doi.org/10.1182/blood.V130.Suppl_1.2930.2930

Published: 2017

Journal Articles

Genomic Landscape of Primary Cutaneous Diffuse Large B Cell Lymphoma, Leg Type

Xiaolong Alan Zhou, MD MSc, Alexander Wenzel, BS, Jingyi Yang, BS, Maria Estela Martinez-Escala, MD, Joan Guitart, MD, Amir Behdad, MD, Lorenzo Cerroni, MD, Jaehyuk Choi

Blood (2017) 130 (Supplement 1): 1464.

https://doi.org/10.1182/blood.V130.Suppl_1.1464.1464

Published: 2017

Journal Articles

Vemurafenib in Advanced Patients with Hairy Cell Leukemia (HCL): Results of the Acsé Phase II Trial

Xavier Troussard, MD, Laure Montané, Mourad Tiab, Carine Chaleteix, MD, Isabelle Grulois, Clothilde Lindet, Delphine Legoupil, Frederic Kohser, Diane Pannier, Frederic Maloisel, Pierre Bories, Céline AIT Oukhatar, Natalie Hoog Labouret, Jean-Yves Blay, MD PhD

Blood (2017) 130 (Supplement 1): 156.

https://doi.org/10.1182/blood.V130.Suppl_1.156.156

Published: 2017

Journal Articles

The Chemotherapy-Free Combination of Vemurafenib and Rituximab Produces Deep and Durable Responses in Relapsed or Refractory Hairy Cell Leukemia (HCL) Patients

Enrico Tiacci, Luca De Carolis, Francesco Zaja, MD, Monia Capponi, Achille Ambrosetti, Eugenio Lucia, Agostino Antolino, Alessandro Pulsoni, MD, Samantha Ferrari, MD, Pier Luigi Zinzani, MD, Luigi Rigacci, Gianluca Gaidano, MD PhD, Roberta Della Seta, Natalia Frattarelli, Paolo Falcucci, Giuseppe Visani, Robin Foà, MD, Brunangelo Falini, MD

Blood (2017) 130 (Supplement 1): 409.

https://doi.org/10.1182/blood.V130.Suppl_1.409.409

Published: 2017

Journal Articles

Targeted therapies in 54 patients with Erdheim-Chester disease, including follow-up after interruption (the LOVE study)

Fleur Cohen Aubart, Jean-François Emile, Fabrice Carrat, Frédéric Charlotte, Neila Benameur, Jean Donadieu, Philippe Maksud, Ahmed Idbaih, Stéphane Barete, Khê Hoang-Xuan, Zahir Amoura, Julien Haroche

Blood (2017) 130 (11): 1377–1380.

https://doi.org/10.1182/blood-2017-03-771873

Published: 2017

Includes: Supplemental data

Journal Articles

Real-Time Genomic Profiling Identifies Novel Mutations and Improved Therapy for Histiocytoses

Lynn Lee, MD, Anjelika Gasilina, Jayeeta Roychoudhury, PhD, Jason Clark, Francis X McCormack, MD, Joseph Gerald Pressey, MD, Robert B. Lorsbach, MD PhD, Siraj M Ali, MD PhD, Mark Bailey, MSc, Philip Stevens, PhD, Jeffrey S Ross, MD, Vincent A. Miller, MD, Nicolas Nassar, PhD, Ashish R Kumar, MBBS, PhD

Blood (2016) 128 (22): 2723.

https://doi.org/10.1182/blood.V128.22.2723.2723

Published: 2016

NARROW

Transcriptomic landscape of circulating mononuclear phagocytes in Langerhans cell histiocytosis at the single-cell level

Classification and Prognosis of Central Nervous System Involvement in Erdheim-Chester Disease

Low-Dose BRAF-Inhibitors in the Treatment of Histiocytic Disorders with the BRAF-V600E Mutation

First Line Chemo-Free Therapy with the BRAF Inhibitor Vemurafenib Combined with Obinutuzumab Is Effective in Patients with Hcl

Moxetumomab Pasudotox-Tdfk in Heavily Pretreated Patients with Relapsed/Refractory Hairy Cell Leukemia (HCL): Long-Term Follow-up from the Pivotal Phase 3 Trial

Identification of Genotype-Specific Therapeutic Vulnerabilities By Comparative Dynamic BH3 Profiling Analysis of Human and Murine CLL

High-Risk Langerhans Cell Histiocytosis in Infants Exhibits Malignant Features in a Xenograft Model but Responds Durably to Targeted Therapy

Acquired Resistance to BRAF Inhibition in Hcl Is Rare and Retreatment with Vemurafenib at Relapse Can Induce High Response Rates: Final Results of a Phase II Trial of Vemurafenib in Relapsed Hcl

Clinical and PET Responses to Long-Term High-Dose Interferon-α Treatment Among Patients with Erdheim-Chester Disease

Treatment with Combination of Dabrafenib and Trametinib in Patients with Recurrent/Refractory BRAF V600E-Mutated Hairy Cell Leukemia (HCL)

Long-Term Follow-up Identifies Double Hit and Key Mutations As Impacting Progression Free and Overall Survival in Multiple Myeloma

Feasibility and Benefit of Molecularly-Informed Enrollment into Personalized Therapies or Early Phase Trials for Patients with Relapsed or Refractory Multiple Myeloma

Clonal Hematopoiesis in Erdheim-Chester Disease

Phase 2 Trial of Single-Agent Cobimetinib for Adults with BRAF V600-Mutant and Wild-Type Histiocytic Disorders

BRAF-V600E in Peripheral Mononuclear Cells and Microglia-like Brain Cells Suggest Hematopoietic Origin of Langerhans Cell Histiocytosis-Associated Neurodegeneration

Genomic Landscape of Primary Cutaneous Diffuse Large B Cell Lymphoma, Leg Type

Vemurafenib in Advanced Patients with Hairy Cell Leukemia (HCL): Results of the Acsé Phase II Trial

The Chemotherapy-Free Combination of Vemurafenib and Rituximab Produces Deep and Durable Responses in Relapsed or Refractory Hairy Cell Leukemia (HCL) Patients

Targeted therapies in 54 patients with Erdheim-Chester disease, including follow-up after interruption (the LOVE study)

Real-Time Genomic Profiling Identifies Novel Mutations and Improved Therapy for Histiocytoses

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only